PRECISION BIOSCIENCES INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
PRECISION BIOSCIENCES INC (DTIL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $2.94 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-26
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $2.94M, a 51.56% decline from fiscal 2023.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $6.08M, a 60.37% increase from fiscal 2022.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $3.79M, a 27.66% decline from fiscal 2021.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $5.24M, a 23.73% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $2.94M 10-K · filed 2025-03-26 |
| 2023-12-31 | $6.08M 10-K · filed 2025-03-26 |
| 2022-12-31 | $3.79M 10-K · filed 2024-03-27 |
| 2021-12-31 | $5.24M 10-K · filed 2023-03-09 |
| 2020-12-31 | $6.87M 10-K · filed 2022-03-15 |
| 2019-12-31 | $4.81M 10-K · filed 2021-03-18 |
| 2018-12-31 | $1.93M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |